Long-term safety of CAR-T cell therapy for B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows patients who completed a previous CAR-T cell therapy trial to check its long-term safety and how well it continues to work against B-cell lymphomas or leukemias.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished all study visits and procedures in the earlier trial (HemC101-01-01).
- You cannot have a life-threatening infection that is not under control.
- You cannot be receiving certain other treatments like steroids, chemotherapy, or cell therapies.
- If you are a woman who can become pregnant, you need a negative pregnancy test.
- You must have followed the previous study rules properly, according to the doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.